Skip Navigation

Digestive Diseases Statistics Clinical Trials Awareness and Prevention Series
Celiac Disease Awareness Campaign Resources Order About NDDIC Información en Español
dots
A to Z list of Digestive Diseases Easy-to-Read Publications Spanish-language Publications Awareness and Prevention Series
Email to a friend  Email to a friend icon
Print this page    Print this page icon

Winter 2002–2003
CONTENTS

73 Million Americans Seek Health Information on the Web

Digestive Diseases Organizations for Professionals

Digestive Diseases Organizations for Patients

Dr. Hoofnagle Receives Awards

Dr. Lipman Receives Award

NIH Consensus Conferences Home In on ECRP and Hepatitis C

Vital Statistics

What's New From NDDIC?

What's New in CHID?

A New Website for NDDIC

Online Catalog and Credit Cards Will Make Ordering NIDDK Publications Easier in 2003

NIDDK Seeks Feedback on Clearinghouse Services

Home : About NDDIC : NDDIC News : Winter 2002–2003
 

NDDIC News

Dr. Hoofnagle Receives Awards

Jay Hoofnagle, M.D., director of the Division of Digestive Diseases and Nutrition at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), recently received the American Association for the Study of Liver Diseases (AASLD) Distinguished Achievement Award, which honors individual researchers for sustained scientific contributions to the field of liver disease. Earlier in 2002, Dr. Hoofnagle also received the Gold Medal from the Canadian Association for the Study of the Liver for contributions to liver disease research.

Dr. Hoofnagle

"He's been a pivotal figure in three areas," says NIDDK's Dr. Leonard Seeff, who presented the AASLD award. "He's trained outstanding physicians in the field, he's a leading figure in treating viral hepatitis, and he's been an important figure in supporting research on liver and gastroenterological diseases."

Dr. Hoofnagle's findings have provided the scientific underpinnings of what have become standard treatments for many people with hepatitis C. In the 1980s, he and his colleagues at the National Institutes of Health (NIH) began evaluating alpha interferon's antiviral potential in hepatitis B and hepatitis C, then known as non-A, non-B hepatitis. At the time, few people believed that viral hepatitis could be treated. The pharmaceutical industry became interested when Dr. Hoofnagle showed that long-term therapy with interferon could control chronic hepatitis C in some patients.

He continues to run clinical trials and to organize national and international educational opportunities for those who treat hepatitis. In 1997, he organized the NIH Consensus Development Conference on the Management of Hepatitis C. In 1999, he co-organized an international symposium on hepatitis C and related viruses, as well as NIH workshops on alternative and complementary medicine in chronic liver disease and on hepatitis C in African Americans. He has written more than 300 research articles and has authored or coauthored more than 50 book chapters.

[Top]

NIH Publication No. 03–4552
March 2003

  

dot

Digestive Diseases Home | Digestive Diseases A to Z | Statistics | Clinical Trials | Awareness and Prevention Series | Celiac Disease Awareness Campaign | Additional Resources | Order Publications | About Us | Información en Español |

Contact Us | NIDDK Health Information

The NDDIC is a service of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.

National Digestive Diseases Information Clearinghouse
2 Information Way
Bethesda, MD 20892–3570
Phone: 1–800–891–5389
TTY: 1–866–569–1162
Fax: 703–738–4929
Email: nddic@info.niddk.nih.gov

Privacy | Disclaimer | Accessibility | PDF versions require the free Acrobat® Reader® software for viewing.
H H S logo - link to U. S. Department of Health and Human Services
NIH logo - link to the National Institute of Health
NIDDK logo - link to the National Institute of Diabetes and Digestive and Kidney Diseases